

Marianna Koczywas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3156008/publications.pdf>

Version: 2024-02-01

67
papers

1,286
citations

394421

19
h-index

377865

34
g-index

67
all docs

67
docs citations

67
times ranked

1902
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 74-89.	9.4	133
2	Patient-defined goals and preferences among adults with advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 509-509.	1.6	0
3	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.	2.4	12
4	Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management. <i>Clinical Journal of Oncology Nursing</i> , 2022, 26, 165-175.	0.6	1
5	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	10.7	49
6	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
7	A Palliative Care Intervention for Patients on Phase 1 Studies. <i>Journal of Palliative Medicine</i> , 2021, 24, 846-856.	1.1	15
8	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
9	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2021, 39, 9007-9007.	1.6	24
10	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). <i>Journal of Clinical Oncology</i> , 2021, 39, 9077-9077.	1.6	29
11	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
12	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
13	The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1498-1505.	2.5	8
14	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16266.	0.5	4
15	Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630. , 2021, , .		2
16	Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa067.	2.9	7
17	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756.	2.8	36
18	A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study. <i>European Journal of Oncology Nursing</i> , 2020, 49, 101855.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	1.4	29
20	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
21	Dissemination and Implementation of Palliative Care in Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 995-1001.	1.6	17
22	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
23	Spirituality in cancer patients on phase 1 clinical trials. <i>Psycho-Oncology</i> , 2020, 29, 1077-1083.	2.3	9
24	A randomized trial of a palliative care intervention for patients on phase I studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12001-12001.	1.6	2
25	Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12010-12010.	1.6	75
26	Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9058-9058.	1.6	16
27	Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9630-TPS9630.	1.6	1
28	Validity of patient-reported outcomes to describe the symptom experience of patients enrolled on phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12107-12107.	1.6	0
29	Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21503-e21503.	1.6	0
30	Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9055-9055.	1.6	0
31	Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21562-e21562.	1.6	0
32	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
33	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
34	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
35	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
36	Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 21, 100155.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. <i>Lung Cancer</i> , 2019, 133, 136-143.	2.0	21
38	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	2.6	36
39	S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8523-8523.	1.6	3
40	Precision medicine and actionable alterations in lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20707-e20707.	1.6	0
41	Identifying patient-reported anxiety and depression in older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11556-11556.	1.6	0
42	Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18192-e18192.	1.6	0
43	Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1518-1518.	1.6	0
44	Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20713-e20713.	1.6	0
45	Patient perspectives on participation in phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 48-48.	1.6	1
46	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1183-1188.	1.1	12
47	Phase 1B Study of Mometinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. <i>Clinical Lung Cancer</i> , 2018, 19, e853-e859.	2.6	21
48	Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8515-8515.	1.6	44
49	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9025-9025.	1.6	23
50	The integrated care service: Impact of a multidisciplinary supportive care service for medical oncology patients in a NCI-designated cancer center.. <i>Journal of Clinical Oncology</i> , 2018, 36, 134-134.	1.6	0
51	Goals of care and advanced care planning in phase I trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 80-80.	1.6	1
52	KRAS in non-small cell lung cancer: Single institution experience—What factors are involved?. <i>Journal of Clinical Oncology</i> , 2017, 35, 11624-11624.	1.6	0
53	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
54	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , 2016, 48, 852-860.	6.7	88

#	ARTICLE	IF	CITATIONS
55	Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. <i>Annals of Thoracic Surgery</i> , 2016, 101, 495-503.	1.3	33
56	SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8537-8537.	1.6	6
57	Integration of palliative care for patients with solid tumors on phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 138-138.	1.6	6
58	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 3298-3306.	4.1	32
59	Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer. <i>Cancer</i> , 2015, 121, 3737-3745.	4.1	110
60	Pulmonary Rehabilitation and Palliative Care for the Lung Cancer Patient. <i>Journal of Hospice and Palliative Nursing</i> , 2015, 17, 462-468.	0.9	15
61	Interdisciplinary Palliative Care for Patients With Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 758-767.	1.2	155
62	ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7511-7511.	1.6	5
63	Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8087-8087.	1.6	7
64	Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9536-9536.	1.6	0
65	Interdisciplinary palliative care for patients with lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 130-130.	1.6	0
66	Longitudinal Changes in Function, Symptom Burden, and Quality of Life in Patients with Early-Stage Lung Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1788-1797.	1.5	35
67	Interdisciplinary Palliative Care Intervention in Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 736-744.	2.6	24